<DOC>
	<DOCNO>NCT00494481</DOCNO>
	<brief_summary>To assess efficacy ZD6474 combination docetaxel treatment ABC use progression event count methodology</brief_summary>
	<brief_title>E3 Breast Cancer Taxotere Combination</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Females histological/cytological confirmation breast cancer . Subjects measurable lesion bone lesion Previous radiotherapy within 6 week Significant cardiac event , arrhythmias cardiac condition</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Zactima</keyword>
</DOC>